These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28178720)

  • 1. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.
    Saglam O; Xiong Y; Marchion DC; Strosberg C; Wenham RM; Johnson JJ; Saeed-Vafa D; Cubitt C; Hakam A; Magliocco AM
    Cancer Control; 2017 Jan; 24(1):89-95. PubMed ID: 28178720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
    Maeda O; Shibata K; Hosono S; Fujiwara S; Kajiyama H; Ino K; Nawa A; Tamakoshi K; Kikkawa F
    Int J Cancer; 2012 Jan; 130(1):113-21. PubMed ID: 21328338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
    Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
    Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
    Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
    Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Shu T; Li Y; Wu X; Li B; Liu Z
    Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
    De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
    Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma].
    Li L; Zhong YP; Zhang W; Zhang JQ; Yao ZQ
    Ai Zheng; 2004 May; 23(5):568-72. PubMed ID: 15142456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
    Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.